Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Freeman

Showing results (231-240 of 244) with videos related to

Pageof 25
Sort By:
BJU International|June 29, 2023
External validation of a risk model predicting failure of salvage focal ablation for prostate cancerAlexander Light, Max Peters, Deepika Reddy, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
European Urology|April 4, 2022
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After RadiotherapyTaimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|March 22, 2024
The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus RecommendationsAlexander Light, Nikhil Mayor, Emma Cullen, et al.
European Urology|January 21, 2023
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605]Taimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
The Lancet. Oncology|March 3, 2022
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory studyAlistair D R Grey, Rebecca Scott, Bina Shah, et al.
Scientific Reports|October 15, 2020
A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologistsLina Maria Carmona Echeverria, Aiman Haider, Alex Freeman, et al.
European Urology|April 22, 2020
Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS StudyAhmed El-Shater Bosaily, Elena Frangou, Hashim U Ahmed, et al.
Radiology|December 13, 2022
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS TrialVasilis Stavrinides, Joseph M Norris, Solon Karapanagiotis, et al.
European Urology|October 14, 2020
False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMISVasilis Stavrinides, Tom Syer, Yipeng Hu, et al.
Pageof 25

Showing results (231-240 of 244) with videos related to

Sort By:
Pageof 25
BJU International|June 29, 2023
External validation of a risk model predicting failure of salvage focal ablation for prostate cancerAlexander Light, Max Peters, Deepika Reddy, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
European Urology|April 4, 2022
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After RadiotherapyTaimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|March 22, 2024
The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus RecommendationsAlexander Light, Nikhil Mayor, Emma Cullen, et al.
European Urology|January 21, 2023
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605]Taimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
The Lancet. Oncology|March 3, 2022
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory studyAlistair D R Grey, Rebecca Scott, Bina Shah, et al.
Scientific Reports|October 15, 2020
A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologistsLina Maria Carmona Echeverria, Aiman Haider, Alex Freeman, et al.
European Urology|April 22, 2020
Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS StudyAhmed El-Shater Bosaily, Elena Frangou, Hashim U Ahmed, et al.
Radiology|December 13, 2022
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS TrialVasilis Stavrinides, Joseph M Norris, Solon Karapanagiotis, et al.
European Urology|October 14, 2020
False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMISVasilis Stavrinides, Tom Syer, Yipeng Hu, et al.
Pageof 25